Association between IL-1B (-511)/IL-1RN (VNTR) polymorphisms and type 2 diabetes: a systematic review and meta-analysis

被引:8
作者
Jiao, Juan [1 ,2 ]
Wang, Zhaoping [1 ]
Guo, Yanfei [3 ]
Liu, Jie [2 ]
Huang, Xiuqing [1 ]
Ni, Xiaolin [1 ]
Gao, Danni [1 ,4 ]
Sun, Liang [1 ]
Zhu, Xiaoquan [1 ]
Zhou, Qi [1 ]
Yang, Ze [1 ]
Yuan, Huiping [1 ]
机构
[1] Chinese Acad Med Sci, Key Lab Geriatr, Beijing Inst Geriatr,Inst Geriatr Med, Beijing Hosp,Natl Ctr Gerontol,Natl Hlth Commiss, Beijing, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Dept Clin Lab, Med Ctr 7, Beijing, Peoples R China
[3] Chinese Acad Med Sci, Dept Resp & Crit Care Med, Natl Ctr Gerontol, Beijing Hosp,Inst Geriatr Med, Beijing, Peoples R China
[4] Peking Univ, Sch Clin Med 5, Beijing Hosp, Beijing, Peoples R China
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
IL-1B (-511); IL-1RN (VNTR); Polymorphism; Type 2 diabetes mellitus; Meta-analysis; RECEPTOR ANTAGONIST GENE; ISLET-ASSOCIATED MACROPHAGES; ENHANCED IL-1-BETA; ALLELE; INTERLEUKIN-1; INFLAMMATION; MELLITUS; SUSCEPTIBILITY; -511C/T; CANCER;
D O I
10.7717/peerj.12384
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Interleukin-1 (IL-1) plays an essential role in the immune pro-inflammatory process, which is regarded as one of many factors in the development of type 2 diabetes mellitus (T2DM). Several case-control studies have illustrated the association of the IL-1B (-511) (rs16944, Chr 2:112,837,290, C/T Intragenic, Transition Substitution) and IL-1RN (VNTR) (gene for IL-1 receptor antagonist, IL-1RA, 86 bp tandem repeats in intron 2) polymorphisms with T2DM risk. However, the results were inconsistent and inconclusive. We performed a meta-analysis (registry number: CRD42021268494) to assess the association of the IL-1B (-511) and IL-1RN (VNTR) polymorphisms with T2DM risk. Random-effects models were applied to calculate the pooled ORs (odds ratios) and 95% CIs (confidence intervals) to test the strength of the association in the overall group and subgroups stratified by ethnicity, respectively. Between-study heterogeneity and publication bias were evaluated by the Q-test, I-2 statistic, Harbord test, and Peters test accordingly. Sensitivity analyses were also performed. A total of 12 publications evaluating the association of IL-1B (-511) and IL-1RN (VNTR) polymorphisms with the risk of T2DM development were included. The meta-analysis showed that IL-1RN (VNTR) was related to the increasing development of T2DM risk in the recessive model (OR = 1.62, 95% CI [1.09-2.42], P-het = 0.377, P-z = 0.018) and in the homozygous model (OR = 2.02, 95% CI [1.07-3.83], P-het = 0.085, P-z = 0.031), and the IL-1RN 2* allele was found a significant association with evaluated T2DM risk in all ethnicities (OR = 2.08, 95% CI [1.43-3.02], P-het < 0.001, P-z < 0.001) and in EA (OR = 2.01, 95% CI [1.53-2.66], P-het = 0.541, P-z < 0.001). Moreover, stratification by ethnicity revealed that IL-1B (-511) was associated with a decreased risk of T2DM in the dominant model (OR=0.76, 95% CI [0.59-0.97], P-het = 0.218, P-z = 0.027) and codominant model (OR = 0.73, 95% CI [0.54-0.99], P-het = 0.141, P-z = 0.040) in the East Asian (EA) subgroup. Our results suggest that the IL-1RN 2* allele and 2*2* homozygous polymorphism are strongly associated with increasing T2DM risk and that the IL-1B (-511) T allele polymorphism is associated with decreasing T2DM risk in the EA subgroup.
引用
收藏
页数:18
相关论文
共 48 条
[1]   Genetic association of interleukin-1β (-511C/T) and interleukin-1 receptor antagonist (86 bp repeat) polymorphisms with Type 2 diabetes mellitus in North Indians [J].
Achyut, B. R. ;
Srivastava, Akanksha ;
Bhattacharya, Sandeep ;
Mittal, Balraj .
CLINICA CHIMICA ACTA, 2007, 377 (1-2) :163-169
[2]   Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond [J].
Aday, Aaron W. ;
Ridker, Paul M. .
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2018, 5
[3]  
Blakemore AIF, 1996, HUM GENET, V97, P369, DOI 10.1007/BF02185776
[4]   How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes [J].
Boeni-Schnetzler, Marianne ;
Donath, Marc Y. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (02) :263-268
[5]   Increased interleukin (IL)-1β messenger ribonucleic acid expression in β-cells of individuals with type 2 diabetes and regulation of IL-1β in human islets by glucose and autostimulation [J].
Boni-Schnetzler, Marianne ;
Thorne, Jeffrey ;
Parnaud, Geraldine ;
Marselli, Lorella ;
Ehses, Jan A. ;
Kerr-Conte, Julie ;
Pattou, Francois ;
Halban, Philippe A. ;
Weir, Gordon C. ;
Donath, Marc Y. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (10) :4065-4074
[6]  
[曹勇 Cao Yong], 2013, [免疫学杂志, Immunological Journal], V29, P503
[7]  
DANIS VA, 1995, CLIN EXP IMMUNOL, V99, P303
[8]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188
[9]   The role of the interleukin-1 receptor antagonist in blocking inflammation mediated by interleukin-1 [J].
Dinarello, CA .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (10) :732-734
[10]   Role of IL-1β in type 2 diabetes [J].
Dinarello, Charles A. ;
Donath, Marc Y. ;
Mandrup-Poulsen, Thomas .
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2010, 17 (04) :314-321